The American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists appreciates the Food and Drug Administration’s (FDA’s) continuing efforts to review and advise the nation on the safe and effective use of hydroxychloroquine, chloroquine, and other medications to prevent and treat coronavirus. We recognize the body of evidence for addressing the COVID-19 global pandemic is evolving rapidly, requiring vigilant yet timely decision making.

We emphasize that the FDA’s recent announcement to cancel the emergency use authorizations for hydroxychloroquine and chloroquine for certain hospitalized patients with COVID-19 does not apply to other evidence-based uses of these medications for conditions such as rheumatoid arthritis and lupus. Our organizations continue to advocate for medication-use policies that ensure patients who need hydroxychloroquine and chloroquine do not face unintended barriers to evidence-based care.

We encourage patients and healthcare providers to consult the FDA’s Frequently Asked Questions on the Revocation of the EUA for Hydroxychloroquine and Chloroquine Phosphate, and COVID-19 related information and resources available from our three organizations.

Media Contact:

Robert J. Mills

ph: (312) 464-5970

[email protected]

About the American Medical Association

The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care.  The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.

Featured Stories